Use of intravitreal bevacizumab for the treatment of secondary glaucoma caused by metastatic iris tumor

Basit Öğe Kaydı
dc.authorid0000-0003-0668-3749
dc.contributor.authorAydın, Rukiye
dc.contributor.authorTezel, Tongalp
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:33Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:33Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000435291400003
dc.descriptionPubMed ID: 29613980
dc.description.abstractPurpose:The purpose of this article was to report the efficacy of intravitreal bevacizumab to resolve secondary angle-closure glaucoma caused by biliary tract carcinoma metastasis to the iris.Materials and Methods:A 52-year-old white woman who was under systemic chemotherapy for biliary tract carcinoma presented with a metastatic tumor in the left iris. At presentation, her visual acuity was at the 20/50 level. The tumor was occupying the nasal half of the iris, and had already occupied 5.5 clock hours of the angle, resulting in intraocular pressure elevation to 34mmHg. Several small clumps of tumor seeds were also observed on the iris and along the angle. Her intraocular pressure remained high despite full medical therapy with dorzolamide, timolol, brimonidine, and oral acetozolamide. Because of the vascularized nature of the tumor, antivascular endothelial growth factor (anti-VEGF) treatment with 3 repeated injections of bevacizumab (1.25mg/0.05mL) was applied 1-month apart. Bevacizumab treatment resulted in an abrupt decrease in tumor mass and disappearance of tumoral seeds from the anterior chamber. The patient's vision improved to 20/20, and intraocular pressure decreased to normal levels.Conclusions:Anti-VEGF treatment with intravitreal bevacizumab can restore sight and achieve intraocular pressure control in metastatic iris tumors complicated with secondary glaucoma. Anti-VEGF drugs are viable alternatives for the treatment of secondary angle-closure glaucoma induced by metastatic iris tumors and can prevent enucleation of these eyes.
dc.description.sponsorshipResearch to Prevent Blindness Inc., New York City, NY; Slomo and Cindy Silvian Foundation, New York, NY; TUBITAK, Ankara, Turkeyen_US
dc.description.sponsorshipSupported in part by an unrestricted grant from Research to Prevent Blindness Inc., New York City, NY, Slomo and Cindy Silvian Foundation, New York, NY, and TUBITAK, Ankara, Turkey.en_US
dc.identifier.citationAydın, R. ve Tezel, T. (2018). Use of intravitreal bevacizumab for the treatment of secondary glaucoma caused by metastatic iris tumor. Journal of Glaucoma, 27(6), E113-E116. https://dx.doi.org/10.1097/IJG.0000000000000959
dc.identifier.doi10.1097/IJG.0000000000000959
dc.identifier.endpageE116
dc.identifier.issn1057-0829
dc.identifier.issn1536-481X
dc.identifier.issue6
dc.identifier.scopusqualityQ2
dc.identifier.startpageE113
dc.identifier.urihttps://dx.doi.org/10.1097/IJG.0000000000000959
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2015
dc.identifier.volume27
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofJournal of Glaucomaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectIris Metastasis
dc.subjectBiliary Tract Carcinoma
dc.subjectBevacizumab
dc.subjectSecondary Angle-Closure Glaucoma
dc.titleUse of intravitreal bevacizumab for the treatment of secondary glaucoma caused by metastatic iris tumor
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydın, R..pdf
Boyut:
181.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu